<DOC>
	<DOCNO>NCT01489254</DOCNO>
	<brief_summary>The purpose study demonstrate efficacy safety Synthon 's glatiramer acetate ( GTR ) equivalent Copaxone® ( Teva ) patient relapse remit multiple sclerosis</brief_summary>
	<brief_title>Efficacy Safety GTR Comparison Copaxone®</brief_title>
	<detailed_description>GTR develop Synthon similar version Copaxone® . GTR similar quantitative qualitative composition Copaxone® , regard active substance excipients present dosage form ( pre-filled syringe contain solution injection ) . Introduction GTR anticipated price lower effect give doctor patient choice pharmaceutical armamentarium MS . This trial consist two part : Part 1 multi-country , multi-centre , randomize , double-blind , active placebo-controlled , equivalence trial compare efficacy safety tolerability GTR versus Copaxone® subject RRMS . Eligible subject randomly assign receive daily 20 mg GTR ( Synthon BV ) , 20 mg Copaxone® ( TEVA ) placebo period 9 month . In Part 2 , trial continue open-label uncontrolled trial evaluate efficacy safety long-term treatment GTR . Subjects complete 9-month double-blind period treat open-label 20 mg daily GTR another 15 month .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>Willing able sign write Informed Consent ; Female male subject age 1855 year inclusive time Informed Consent signing ; Diagnosis RRMS accord revise McDonald criterion ; Expanded Disability Status Scale ( EDSS ) score 0.0 include 5.5 ; Neurologically stable evidence relapse within 30 day prior randomization ; Experienced least 1 relapse year first screening assessment ; At least 1 T1weighted Gadolinium enhancing ( T1GdE ) lesion routine brain MRI take within 3 month start screen screen brain MRI ( confirmed central image laboratory ; Having routine brain MRI show maximally 15 T1GdE lesion scan take without subject receive immunomodulatory treatment , routine brain MRI show maximally 5 T1GdE lesion take immunomodulatory treatment , screen MRI show maximally 15 T1GdE lesion ; Must decline initiation continuation treatment available diseasemodifying drug MS , whatever reason , inform respective benefit possible adverse event investigator ; Female subject childbearing potential must agree practice appropriate contraceptive method assess investigator . Any lifethreatening , medically unstable otherwise clinically significant condition finding MS , particular neoplastic disease , seizure disorder , psychiatric disease ; Any clinically significant deviation reference range laboratory test ; Positive laboratory test result human immunodeficiency virus ( HIV ) , HBsAg HCV screening ; Any significant deviation reference range hepatic function ; Positive urine drug screen history substance abuse within year screening ( use illicit prescription drug alcohol constitute abuse pattern opinion investigator ) ; Having treat receive 1. time : glatiramer acetate , cladribine , rituximab , cyclophosphamide , alemtuzumab , immunosuppressive treatment effect potentially last 6 month total lymphoid irradiation bone marrow transplantation 2. within one year screening : mitoxantrone , subject enrol mitoxantrone take cumulative lifetime dose 100 mg/m2 3. within 6 month screen : fingolimod , immunoglobulins and/or monoclonal antibody ( include natalizumab ) , leflunomide , putative MS treatment chronic oral inject corticosteroid inject ACTH ( 30 consecutive day ) 4. within 3 month screen : azathioprine , methotrexate plasma exchange experimental intervention , particular experimental drug 5. within 1 month screening : Interferonβ 1a 1b shortterm oral injectable corticosteroid treatment relapse shortterm ACTH Having , opinion investigator , consecutively fail efficacy ground two full adequate course accept treatment modality ( normally least one year treatment ) ; Pregnancy breastfeeding ; Known hypersensitivity gadoliniumcontaining product , glatiramer acetate mannitol ; Having estimate glomerular filtration rate ( eGFR ) &lt; 50 mL/min/1.73m2 ; Inability undergo ( repeat ) MRI investigation judge investigator , e.g . due claustrophobia , metal implant fragment , tattoos permanent makeup ; Any reason , investigator 's opinion , subject participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Multiple Sclerosis ,</keyword>
	<keyword>Relapsing-Remitting Multiple Sclerosis ,</keyword>
	<keyword>glatiramer acetate ,</keyword>
	<keyword>MRI ,</keyword>
	<keyword>lesion ,</keyword>
	<keyword>MS relapse rate ,</keyword>
	<keyword>Copaxone</keyword>
</DOC>